Published in Onco Targets Ther on November 05, 2013
Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. World J Gastroenterol (2014) 0.92
Toll-like receptor-4 modulation for cancer immunotherapy. Front Immunol (2014) 0.81
The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz) (2015) 0.81
Effects of Alcohol on Tumor Growth, Metastasis, Immune Response, and Host Survival. Alcohol Res (2015) 0.79
Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway. Oncotarget (2016) 0.78
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. J Transl Med (2014) 0.77
Diet and lifestyle factors modify immune/inflammation response genes to alter breast cancer risk and prognosis: the Breast Cancer Health Disparities Study. Mutat Res (2014) 0.77
Mechanisms Underlying the Anti-Inflammatory Effects of Clinacanthus nutans Lindau Extracts: Inhibition of Cytokine Production and Toll-Like Receptor-4 Activation. Front Pharmacol (2016) 0.77
Emerging role of Toll-like receptor 4 in hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.77
Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. Int J Mol Sci (2016) 0.76
Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. Cent Eur J Immunol (2017) 0.75
Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin. Photochem Photobiol (2016) 0.75
Ethanol extract of propolis and its constituent caffeic acid phenethyl ester inhibit breast cancer cells proliferation in inflammatory microenvironment by inhibiting TLR4 signal pathway and inducing apoptosis and autophagy. BMC Complement Altern Med (2017) 0.75
LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer. Infect Agent Cancer (2017) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Cancer-related inflammation. Nature (2008) 34.21
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (1997) 23.92
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol (2007) 12.00
Macrophage activation and polarization. Front Biosci (2008) 11.17
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med (2007) 9.77
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem (2000) 9.07
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009) 8.99
Global cancer statistics. CA Cancer J Clin (1999) 8.82
LPS/TLR4 signal transduction pathway. Cytokine (2008) 6.60
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 5.65
Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun (2000) 5.65
Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science (2007) 5.54
Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol (2002) 5.41
LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol (2005) 5.25
Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29
Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science (2007) 4.01
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol (2006) 3.94
TLR signaling in the gut in health and disease. J Immunol (2005) 3.51
Structures of the toll-like receptor family and its ligand complexes. Immunity (2008) 3.36
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol (2008) 3.30
Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol (2009) 3.27
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology (2004) 3.11
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Retracted Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem (2003) 2.89
Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology (2002) 2.80
Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One (2009) 2.79
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
The evolution and genetics of innate immunity. Nat Rev Genet (2001) 2.60
Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci U S A (2004) 2.43
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull (2005) 2.25
TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 2.18
Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ (2003) 2.11
Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A (2009) 2.07
A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2006) 1.98
Bacterial endotoxin: a trigger factor for alcoholic pancreatitis? Evidence from a novel, physiologically relevant animal model. Gastroenterology (2007) 1.96
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91
Cancer-related inflammation. J Clin Immunol (2012) 1.91
Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol (2004) 1.89
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res (2009) 1.85
Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res (2005) 1.77
Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology (2005) 1.75
Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol (2005) 1.75
TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol (2007) 1.72
TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol (2007) 1.70
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res (2006) 1.69
Role of Toll-like receptors in gastrointestinal malignancies. Oncogene (2008) 1.69
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res (2008) 1.69
Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol (2009) 1.64
Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer (2004) 1.62
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron (2009) 1.60
HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J (2003) 1.59
Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care (2002) 1.59
Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res (2006) 1.59
Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer (2002) 1.57
Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer (2010) 1.53
TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene (2009) 1.52
Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol (2005) 1.49
Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res (2005) 1.49
HPV: from infection to cancer. Biochem Soc Trans (2007) 1.47
Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Toll-like receptors: networking for success. Eur J Immunol (2003) 1.45
Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res (2003) 1.44
Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol (2009) 1.42
LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res (2011) 1.40
Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res (2010) 1.38
Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol (2005) 1.38
Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol (2009) 1.34
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.33
Essential role of MD-2 in TLR4-dependent signaling during Helicobacter pylori-associated gastritis. J Immunol (2004) 1.33
Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol (2003) 1.31
Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res (2007) 1.31
TLR4 signalling in the intestine in health and disease. Biochem Soc Trans (2007) 1.31
Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer (2007) 1.30
Toll-like receptors, inflammation and cancer. Semin Cancer Biol (2005) 1.29
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer (2008) 1.27
The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis (2005) 1.26
Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis (2005) 1.24
Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23
Toll-like receptor signaling in anti-cancer immunity. J Med Invest (2003) 1.22
Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst (2005) 1.21
Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol (2006) 1.20
Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol (2009) 1.19
Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet (2006) 1.18
Bacterial vaginosis and cervical intraepithelial neoplasia. Acta Obstet Gynecol Scand (1994) 1.17
Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol (2007) 1.17
Toll-like receptors in skin. Adv Dermatol (2008) 1.17
Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol (2003) 1.17
Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol (2009) 1.60
6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor γ (PPARγ). Cancer Lett (2013) 0.93
Antiproliferative activity and induction of apoptosis in estrogen receptor-positive and negative human breast carcinoma cell lines by Gmelina asiatica roots. Pharmacognosy Res (2010) 0.80
Antimicrobial activity of Bauhinia tomentosa and Bauhinia vahlii roots. Pharmacogn Mag (2010) 0.77
2-Meth-oxy-4-(prop-2-en-1-yl)phenyl benzoate. Acta Crystallogr Sect E Struct Rep Online (2013) 0.75
2-Meth-oxy-4-(prop-2-en-1-yl)phenyl 2,4-di-chloro-benzoate. Acta Crystallogr Sect E Struct Rep Online (2013) 0.75
The clinical effects of Synsepalum dulcificum: a review. J Med Food (2014) 0.75